20 May Exact Sciences Advances Pipeline Capabilities with Mayo Clinic
Early data on pancreatic cancer detection presented at Digestive Disease Week® 2019
SAN DIEGO, CA – May 20, 2019 – Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive Disease Week (DDW) 2019, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.